地西他滨联合预激方案治疗老年骨髓增生异常综合征的临床效果分析

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (29 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo evaluate the clinical effect of Decitabine combined with pre-excitation regimen in the treatment of senile myelodysplastic syndrome.Methods55 elderly patients with myelodysplastic syndrome who were admitted into our hospital from June 2012 to January 2017 were selected as the study objects.All patients were numbered and randomly divided into two groups,and there were 30 patients in the control group,and 25 patients in the observation group.The patients in the control group were given pre-excitation regimen,while the observation group was given Decitabine combined with pre-excitation regimen.The clinical efficacy of patients between the two groups after treatment were compared.ResultsThe total effective rate was 96.00%in the observation group,which was significantly higher than that in the control group(66.67%)and the observation group had a better curative effect(P<0.05).The incidence of adverse reactions such as impaired liver function,thrombocytopenia and granulocytopenia in the observation group was significantly lower than those in the control group(P<0.05).ConclusionClinical effect of Decitabine combined with pre-excitation regimen in the treatment of senile myelodysplastic syndrome has a significant effect,which is helpful to eliminate the clinical symptoms of patients and promote the recovery of patients as soon as possible,and has an important clinical value.

Key words： Decitabine Pre-excitation regimen Senile myelodysplastic syndrome Clinical effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	PENG Li

Cite this article:

PENG Li. Clinical effect analysis of Decitabine combined with pre-excitation regimen in the treatment of senile myelodysplastic syndrome[J]. 中国当代医药, 2017, 24(18): 25-27.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I18/25

[1]	管俊，姜扬文，孙爱红，等.地西他滨联合半量预激方案对老年急性髓性白血病及高危骨髓增生异常综合征的影响[J].中华临床医师杂志（电子版），2014，8（21）：135-138.
[2]	李斌.地西他滨联合预激方案和传统治疗方案治疗老年骨髓增生异常综合征的有效性和安全性探讨[J].黑龙江医药，2015，28（6）：1268-1270.
[3]	曹静，黄琨，徐敏.地西他滨联合预激方案治疗中高危骨髓增生异常综合征及急性髓系白血病20例分析[J].中外医疗，2016，35（25）：119-121.
[4]	邢丽娜，任金海，蔡圣鑫，等.地西他滨单药或联合预激方案治疗骨髓增生异常综合征及急性髓系白血病的临床分析[J].肿瘤，2015，35（5）：544-549.
[5]	张静人，刘跃均，仇惠英，等.地西他滨联合CAG预激方案治疗急性红白血病55例临床研究[J].中国实用内科杂志，2014，34（11）：1103-1105.
[6]	王芳侠，何爱丽，张王刚，等.小剂量地西他滨联合G-HA预激方案治疗高危MDS的临床研究[J].西部医学，2016，28（10）：1389-1392.
[7]	邢富兴，韩斯琴.治疗老年骨髓增生异常/骨髓增殖性重叠综合征MDS/MPD转化的急性髓系白血病的疗效观察[J].当代医学，2014，20（35）：138-139.
[8]	陈亚丽，郭荣，李英梅，等.减低剂量地西他滨治疗中高危骨髓增生异常综合征的效果分析[J].河南医学研究，2016，25（4）：667-668.
[9]	薄利魁.地西他滨单药五天方案治疗复杂核型骨髓增生异常综合征和急性髓系白血病临床分析[J].健康前沿，2016，23（1）：67-68.
[10]	周仲昊，赵晓红，陆时运，等.两种化疗方案治疗高龄MDS患者继发AML的临床对比研究[J].中国实验血液学杂志，2016，24（5）：1484-1488.
[11]	孙妍珺，徐杨，吴德沛，等.地西他滨联合预激方案治疗53例复发难治正常核型急性髓系白血病的疗效分析[J].中华血液学杂志，2015，36（12）：1025-1030.
[12]	贡蓉，马梁明，乔振华，等.采用地西他滨联合CIG双预激治疗三例染色体核型异常的老年急性髓系白血病的临床观察并文献复习[J].中国药物与临床，2016，16（9）：1308-1310.
[13]	王斐，徐淑琴，崔巍，等.流式细胞术检测骨髓增生异常综合征免疫表型分析及临床应用前景[J].中华检验医学杂志，2016，39（5）：332-335.
[14]	崔巍，金正明，曹晶，等.地西他滨联合HAAG方案治疗进展期急性髓系白血病疗效分析[J].第三军医大学学报，2016，38（12）：1379-1384.
[15]	Lu XC，Yang B，Zhu HL，et al.Application of bioinformatics analysis to optimize amifostine combination therapeutic regimen of myelodysplastic syndrome[J].Zhonghua Yi Xue Za Zhi，2009，89（26）：1834-1837.
[16]	喻艳，孙爱宁，陈苏宁，等.红系增生明显活跃的骨髓增生异常综合征临床分析[J].中华内科杂志，2017，56（1）：29-33.
[17]	张苏东，冯四洲.异基因造血干细胞移植治疗骨髓增生异常综合征研究进展[J].中华血液学杂志，2016，37（5）：432-436.
[18]	张彤彤，孙爱宁，潘金兰，等.单中心550例骨髓增生异常综合征患者临床特点、细胞遗传学特征及预后分析[J].中华血液学杂志，2016，37（10）：864-869.